Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00814060 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)
A Phase 1 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00814060 is a Phase 1 study that has completed, run by Puma Biotechnology. The registered enrollment target is 24 participants.
The verdict
NCT00814060, a Phase 1 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.
Interventions
- DRUG neratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00814060
The ClinicalTrials.gov registry entry for NCT00814060 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which neratinib is the first listed.
NCT00814060 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00814060 about?
NCT00814060 is a clinical study titled "Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)". This study will examine the bioavailability (the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action) of two tablet formulations of Neratinib (HKI-272) compared to the capsule formulation.
What is the current status of trial NCT00814060?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2009-01. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00814060?
The interventions under investigation include: neratinib (DRUG).
Who is sponsoring clinical trial NCT00814060?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.